全文获取类型
收费全文 | 31645篇 |
免费 | 2813篇 |
国内免费 | 1405篇 |
专业分类
耳鼻咽喉 | 85篇 |
儿科学 | 357篇 |
妇产科学 | 307篇 |
基础医学 | 4754篇 |
口腔科学 | 286篇 |
临床医学 | 1746篇 |
内科学 | 4924篇 |
皮肤病学 | 453篇 |
神经病学 | 3037篇 |
特种医学 | 471篇 |
外国民族医学 | 8篇 |
外科学 | 1807篇 |
综合类 | 4678篇 |
现状与发展 | 9篇 |
预防医学 | 599篇 |
眼科学 | 321篇 |
药学 | 5219篇 |
11篇 | |
中国医学 | 3074篇 |
肿瘤学 | 3717篇 |
出版年
2024年 | 27篇 |
2023年 | 442篇 |
2022年 | 730篇 |
2021年 | 1206篇 |
2020年 | 1128篇 |
2019年 | 940篇 |
2018年 | 913篇 |
2017年 | 1107篇 |
2016年 | 1164篇 |
2015年 | 1241篇 |
2014年 | 2082篇 |
2013年 | 2389篇 |
2012年 | 1998篇 |
2011年 | 2307篇 |
2010年 | 1844篇 |
2009年 | 1740篇 |
2008年 | 1785篇 |
2007年 | 1607篇 |
2006年 | 1501篇 |
2005年 | 1278篇 |
2004年 | 1142篇 |
2003年 | 990篇 |
2002年 | 839篇 |
2001年 | 633篇 |
2000年 | 582篇 |
1999年 | 472篇 |
1998年 | 399篇 |
1997年 | 372篇 |
1996年 | 283篇 |
1995年 | 332篇 |
1994年 | 295篇 |
1993年 | 249篇 |
1992年 | 186篇 |
1991年 | 165篇 |
1990年 | 169篇 |
1989年 | 145篇 |
1988年 | 114篇 |
1987年 | 93篇 |
1986年 | 92篇 |
1985年 | 170篇 |
1984年 | 143篇 |
1983年 | 94篇 |
1982年 | 99篇 |
1981年 | 93篇 |
1980年 | 68篇 |
1979年 | 49篇 |
1978年 | 39篇 |
1977年 | 39篇 |
1976年 | 40篇 |
1975年 | 17篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
41.
辅助化疗有助于改善高危II/III期结直肠癌患者的生存。然而,辅助化疗的不良反应影响患者的生活质量,严重的不良反应甚至可能导致化疗的延期或终止,使得患者不能从辅助化疗中获益。中国中医科学院西苑医院杨宇飞教授根据多年临床经验,创新性提出辅助化疗期的“两阶段三部曲”,即补肾健脾序贯疗法,第1阶段应用自拟六君安胃方健脾和胃,针对化疗导致的胃肠道反应;第2阶段运用芪菟二至方健脾益肾,针对化疗导致的骨髓抑制;以及辛凉解表感冒方,针对化疗期间的外感。临床应用取得了显著的疗效。文章详细阐述“两阶段三部曲”提出的背景及其主要内容。 相似文献
42.
43.
Xianxiu Ji Huikang Xie Ren Zhu Bin Chen Sen Jiang Jie Luo 《The Journal of international medical research》2021,49(2)
ObjectiveTo compare the baseline clinical characteristics between patients with ROS1-positive and ALK-positive advanced non-small cell lung cancer (NSCLC), and the correlations of these subtypes with the distribution of metastases.MethodsWe compared the clinical characteristics and imaging features of patients with ROS1-positive and ALK-positive NSCLC using statistical methods.ResultsData for 232 patients were analyzed. Compared with ALK-positive NSCLC, ROS1-positive NSCLC was more likely to occur in women (71% vs 53%), and primary lesions ≤3 cm were more common in patients with ROS1-positive compared with ALK-positive NSCLC (58% vs 37%). There was no significant difference in the distribution of metastases between the two groups. Subgroup analysis within the ROS1-positive group showed that, compared with primary lesions >3 cm, primary lesions ≤3 cm were more likely to present as peripheral tumors (72% vs 43%) and more likely to exhibit non-solid density (44% vs 4%).ConclusionsAlthough ROS1-positive and ALK-positive NSCLCs show similar clinical features, the differences may help clinicians to identify patients requiring further genotyping at initial diagnosis. 相似文献
44.
Meng Ye Xiang-Jiang Guo Ke-Jia Kan Qi-Hong Ni Jia-Quan Chen Han Wang Xin Qian Guan-Hua Xue Hao-Yu Deng Lan Zhang 《中华医学杂志(英文版)》2021,134(1):73
Background:Arteriosclerosis obliterans (ASO) is a major cause of adult limb loss worldwide. Autophagy of vascular endothelial cell (VEC) contributes to the ASO progression. However, the molecular mechanism that controls VEC autophagy remains unclear. In this study, we aimed to explore the role of the GRB2 associated binding protein 1 (GAB1) in regulating VEC autophagy.Methods:In vivo and in vitro studies were applied to determine the loss of adapt protein GAB1 in association with ASO progression. Histological GAB1 expression was measured in sclerotic vascular intima and normal vascular intima. Gain- and loss-of-function of GAB1 were applied in VEC to determine the effect and potential downstream signaling of GAB1.Results:The autophagy repressor p62 was significantly downregulated in ASO intima as compared to that in healthy donor (0.80 vs. 0.20, t = 6.43, P < 0.05). The expression level of GAB1 mRNA (1.00 vs. 0.24, t = 7.41, P < 0.05) and protein (0.72 vs. 0.21, t = 5.97, P < 0.05) was significantly decreased in ASO group as compared with the control group. Loss of GAB1 led to a remarkable decrease in LC3II (1.19 vs. 0.68, t = 5.99, P < 0.05), whereas overexpression of GAB1 significantly led to a decrease in LC3II level (0.41 vs. 0.93, t = 7.12, P < 0.05). Phosphorylation levels of JNK and p38 were significantly associated with gain- and loss-of-function of GAB1 protein.Conclusion:Loss of GAB1 promotes VEC autophagy which is associated with ASO. GAB1 and its downstream signaling might be potential therapeutic targets for ASO treatment. 相似文献
45.
46.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
47.
Cutaneous histiocytoses constitute a heterogeneous group of diseases characterised by the cutaneous accumulation of cells with the cytological and phenotypic features of macrophages or dendritic cells. The clinical spectrum ranges from self-resolving, skin-limited conditions to severe, multiorgan disease with a high morbidity rate. Until recently, cutaneous histiocytoses were classified according to the immunophenotype of the pathological cells, with differentiation between Langerhans cell histiocytosis (LCH) [CD1a+, CD207 (langerin)+] and non-Langerhans cell histiocytosis (CD68+, CD163+, CD1a?, CD207?). Over the last 12 years, a number of new pathophysiological findings (in particular, molecular pathology results) regarding histiocytoses have contributed to a new classification based on molecular alterations, as well as on clinical and imaging characteristics and the phenotype. The most frequent entities in children are juvenile xanthogranuloma and LCH. 相似文献
48.
《Clinical breast cancer》2022,22(6):507-514
Breast cancer (BC) is a highly metastatic, pathological cancer that significantly affects women worldwide. The mortality rate of BC is related to its heterogeneity, aggressive phenotype, and metastasis. Recent studies have highlighted that the tumor microenvironment (TME) is critical for the interplay between metastasis mediators in BC. BC stem cells, tumor-derived exosomes, circulatory tumor cells (CTCs), and signaling pathways dynamically remodel the TME and promote metastasis. This review examines the cellular and molecular mechanisms governing the epithelial to mesenchymal transition (EMT) that facilitate metastasis. This review also discusses the role of cancer stem cells (CSCs), tumor-derived exosomes, and CTs in promoting BC metastasis. Furthermore, the review emphasizes major signaling pathways that mediate metastasis in BC. Finally, the interplay among CSCs, exosomes, and CTCs in mediating metastasis have been highlighted. Therefore, understanding the molecular cues that mediate the association of CSCs, exosomes, and CTCs in TME helps to optimize systemic therapy to target metastatic BC. 相似文献
49.
50.
目的 探讨负荷渐增式训练对老年小鼠骨骼肌卫星细胞腺苷酸活化蛋白激酶(AMP-activated protein kinase,AMPK)磷酸化的影响。方法 实验小鼠分为 3 组:青年对照组(YC组,n=12)、老年对照组(OC组,n=12)与老年运动组(OT组,n=12)。OT组进行负荷渐增式训练,流式细胞分选技术分离CD45-/CD31-/Sca1-/VCAM(CD106)+细胞群体,分选细胞通过desmin、Myod肌原性染色以及成肌分化诱导培养进行肌卫星细胞鉴定,免疫组化结合Western blotting方法检测肌卫星细胞p-AMPK水平。结果 YC组骨骼肌卫星细胞AMPK及p-AMPK表达水平显著高于OC组(P<0.05);OT组与OC组AMPK表达无明显变化(P>0.05),而OT组p-AMPK表达水平显著高于OC组(P<0.05)。结论 负荷渐增式训练可促进老年小鼠骨骼肌卫星细胞AMPK磷酸化,改善老年小鼠骨骼肌能量代谢。 相似文献